Evaluation of Graft Fibrosis, Inflammation, and Donor-specific Antibodies at Protocol Liver Biopsies in Pediatric Liver Transplant Patients: A Single-center Experience.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
27
1
2021
medline:
25
3
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
The impact of graft fibrosis and inflammation on the natural history of pediatric liver transplants is still debated. Our objectives were to evaluate the evolution of posttransplant fibrosis and inflammation over time at protocol liver biopsies (PLBs), risk factors for fibrosis, presence of donor-specific antibodies (DSAs), and/or their correlation with graft and recipient factors. A single-center, retrospective (2000-2019) cross-sectional study on pediatric liver transplant recipients who had at least 1 PLB, followed by a longitudinal evaluation in those who had at least 2 PLBs, was conducted. Fibrosis was assessed by the Liver Allograft Fibrosis Semiquantitative score, inflammation by the rejection activity index, DSAs by Luminex. A total of 134 PLBs from 94 patients were included. Fibrosis was detected in 87% (30% mild, 45% moderate, and 12% severe), 80% in the portal tracts. There was an increase in fibrosis between the 1-3 and the 4-6 y group (P = 0.01), then it was stable. Inflammation was observed in 44% (30% mild, 13% moderate, and 1% severe), 90% in the portal tracts. Anti-HLA II (IgG) DSAs were detected in 14 of 40 (35%). Portal fibrosis was associated with portal inflammation in the 1-3 y group (P = 0.04). Low immunosuppression levels were correlated with sinusoidal fibrosis (P = 0.04) and DSA positivity (P = 0.006). There was no statistically significant correlation between DSA positivity and the presence of graft fibrosis or inflammation. This study corroborates the concept of an early evolution of silent graft fibrosis. Suboptimal immunosuppression may play a role in the development of fibrosis and DSAs.
Sections du résumé
BACKGROUND
The impact of graft fibrosis and inflammation on the natural history of pediatric liver transplants is still debated. Our objectives were to evaluate the evolution of posttransplant fibrosis and inflammation over time at protocol liver biopsies (PLBs), risk factors for fibrosis, presence of donor-specific antibodies (DSAs), and/or their correlation with graft and recipient factors.
METHODS
A single-center, retrospective (2000-2019) cross-sectional study on pediatric liver transplant recipients who had at least 1 PLB, followed by a longitudinal evaluation in those who had at least 2 PLBs, was conducted. Fibrosis was assessed by the Liver Allograft Fibrosis Semiquantitative score, inflammation by the rejection activity index, DSAs by Luminex.
RESULTS
A total of 134 PLBs from 94 patients were included. Fibrosis was detected in 87% (30% mild, 45% moderate, and 12% severe), 80% in the portal tracts. There was an increase in fibrosis between the 1-3 and the 4-6 y group (P = 0.01), then it was stable. Inflammation was observed in 44% (30% mild, 13% moderate, and 1% severe), 90% in the portal tracts. Anti-HLA II (IgG) DSAs were detected in 14 of 40 (35%). Portal fibrosis was associated with portal inflammation in the 1-3 y group (P = 0.04). Low immunosuppression levels were correlated with sinusoidal fibrosis (P = 0.04) and DSA positivity (P = 0.006). There was no statistically significant correlation between DSA positivity and the presence of graft fibrosis or inflammation.
CONCLUSIONS
This study corroborates the concept of an early evolution of silent graft fibrosis. Suboptimal immunosuppression may play a role in the development of fibrosis and DSAs.
Identifiants
pubmed: 33496554
doi: 10.1097/TP.0000000000003649
pii: 00007890-202201000-00025
doi:
Substances chimiques
HLA Antigens
0
Isoantibodies
0
Doxorubicin
80168379AG
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-95Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Yazigi NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr. 2013;16:207–218.
Evans HM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43:1109–1117.
Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012;18:1333–1342.
Venturi C, Sempoux C, Quinones JA, et al. Dynamics of allograft fibrosis in pediatric liver transplantation. Am J Transplant. 2014;14:1648–1656.
Kelly D, Verkade HJ, Rajanayagam J, et al. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments. Liver Transpl. 2016;22:1593–1602.
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35:397–406.
Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant. 2011;11:1792–1802.
O’Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant. 2014;14:779–787.
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting report: revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18:293–307.
Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16:2816–2835.
Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int. 2015;28:1371–1382.
Grabhorn E, Binder TM, Obrecht D, et al. Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation. 2015;99:1876–1881.
Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation. 2015;99:1416–1422.
Benítez C, Londoño M-C, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013;58:1824–1835.
Lucey MR. Serial liver biopsies: a gateway into understanding the long-term health of the liver allograft. J Hepatol. 2001;34:762–763.
Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation. 2009;87:606–614.
Neuberger J, Wilson P, Adams D. Protocol liver biopsies: the case in favour. Transplant Proc. 1998;30:1497–1499.
Cho JY, Suh KS, Lee HW, et al. The clinical significance of early histological rejection with or without biochemical abnormality in adult living donor liver transplantation for hepatitis B virus related end stage liver disease. Transpl Int. 2007;20:37–44.
Baumann AK, Schlue J, Noyan F, et al. Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts. Liver Transpl. 2016;22:943–955.
Höfer A, Jonigk D, Hartleben B, et al. DSA are associated with more graft injury, more fibrosis, and upregulation of rejection-associated transcripts in subclinical rejection. Transplantation. 2020;104:551–561.
McKiernan P, Mitchell E. Immunosuppression in pediatric liver transplant. D’Antiga L, ed. In: Pediatric Hepatology and Liver Transplantation. 1st ed. Springer International Publishing; 2019:555–564.
Thangarajah D, O’Meara M, Dhawan A. Management of acute rejection in paediatric liver transplantation. Paediatr Drugs. 2013;15:459–471.
McDiarmid SV. Special considerations for immunosuppression in children. Busuttil R, Klintmalm G, eds. In: Transplantation of the Liver. 3rd ed. Saunders-Elsevier; 2015:1289–1316.
Venturi C, Sempoux C, Bueno J, et al. Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. Am J Transplant. 2012;12:2986–2996.
Tambur AR, Campbell P, Claas FH, et al. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant. 2018;18:1604–1614.
Mells G, Neuberger J. Protocol liver allograft biopsies. Transplantation. 2008;85:1686–1692.
Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: a meta-analysis. PLoS One. 2017;12:e0185192.
Vinciguerra T, Brunati A, David E, et al. Transient elastography for non-invasive evaluation of post-transplant liver graft fibrosis in children. Pediatr Transplant. 2018;22.
Briem-Richter A, Ganschow R, Sornsakrin M, et al. Liver allograft pathology in healthy pediatric liver transplant recipients. Pediatr Transplant. 2013;17:543–549.
Hübscher SG. What is the long-term outcome of the liver allograft? J Hepatol. 2011;55:702–717.
Kosola S, Lampela H, Jalanko H, et al. Low-dose steroids associated with milder histological changes after pediatric liver transplantation. Liver Transpl. 2013;19:145–154.
Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl. 2008;14:1582–1587.
Cousin VL, Rougemont A-L, Rubbia-Brandt L, et al. Peripheral donor specific antibodies are associated with histology and cellular subtypes in protocol liver biopsies of pediatric recipients. Transplantation. 2020;104:1633–1643.
Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res. 2012;42:895–903.
Feng S, Demetris AJ, Spain KM, et al. Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. Hepatology. 2017;65:647–660.
Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant. 2012;16:858–865.
Kivelä JM, Kosola S, Peräsaari J, et al. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients. Transpl Int. 2016;29:494–505.
Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol. 2016;27:293–304.
O’Leary JG, Kaneku H, Banuelos N, et al. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant. 2015;15:1003–1013.
Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol. 2015;26:1489–1502.
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167.
Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399.